Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review

Coppin, 2005, Immunotherapy for advanced renal cell cancer, Cochrane Database Syst Rev, CD001425 Negrier, 2007, Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial, Cancer, 110, 2468, 10.1002/cncr.23056 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Sternberg, 2010, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial, J Clin Oncol, 28, 1061, 10.1200/JCO.2009.23.9764 Escudier, 2007, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, Lancet, 370, 2103, 10.1016/S0140-6736(07)61904-7 Hudes, 2007, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838 Motzer, 2008, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet, 372, 449, 10.1016/S0140-6736(08)61039-9 Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108 Bergers, 2003, Tumorigenesis and the angiogenic switch, Nat Rev Cancer, 3, 401, 10.1038/nrc1093 Rini, 2005, Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma, J Clin Oncol, 23, 1028, 10.1200/JCO.2005.01.186 Grander, 1998, Interferon and malignant disease—how does it work and why doesn’t it always?, Acta Oncol, 37, 331, 10.1080/028418698430548 Bracarda, 2010, Redefining the role of interferon in the treatment of malignant diseases, Eur J Cancer, 46, 284, 10.1016/j.ejca.2009.10.013 Porta, 2007, Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents, ScientificWorldJournal, 7, 837, 10.1100/tsw.2007.154 Porta, 2000, Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro, J Cell Physiol, 185, 126, 10.1002/1097-4652(200010)185:1<126::AID-JCP12>3.0.CO;2-2 Porta, 1997, Nitrate plasma level as a marker of nitric oxide production after subcutaneous interleukin 2 immunotherapy, J Natl Cancer Inst, 89, 1545, 10.1093/jnci/89.20.1545 Porta, 2002, Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?, Lung Cancer, 38, 159, 10.1016/S0169-5002(02)00187-3 Presta, 1997, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res, 57, 4593 Karaman, 2008, A quantitative analysis of kinase inhibitor selectivity, Nat Biotechnol, 26, 127, 10.1038/nbt1358 Chow, 2007, Sunitinib: from rational design to clinical efficacy, J Clin Oncol, 25, 884, 10.1200/JCO.2006.06.3602 Kumar, 2007, Pharmacokinetic–pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity, Mol Cancer Ther, 6, 2012, 10.1158/1535-7163.MCT-07-0193 Wilhelm, 2004, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, 7099, 10.1158/0008-5472.CAN-04-1443 Schmelzle, 2000, TOR, a central controller of cell growth, Cell, 103, 253, 10.1016/S0092-8674(00)00117-3 Del Bufalo, 2006, Antianglogenic potential of the mammalian target of rapamycin inhibitor temsirolimus, Cancer Res, 66, 5549, 10.1158/0008-5472.CAN-05-2825 Escudier, 2010, Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival, J Clin Oncol, 28, 2144, 10.1200/JCO.2009.26.7849 Rini, 2008, Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206, J Clin Oncol, 26, 5422, 10.1200/JCO.2008.16.9847 Rini, 2010, Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206, J Clin Oncol, 28, 2137, 10.1200/JCO.2009.26.5561 Bracarda, 2011, Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial, BJU Int, 107, 214, 10.1111/j.1464-410X.2010.09707.x Melichar, 2008, First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma, Ann Oncol, 19, 1470, 10.1093/annonc/mdn161 Motzer, 2002, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma, J Clin Oncol, 20, 289, 10.1200/JCO.20.1.289 Escudier, 2007, Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma, Clin Cancer Res, 13, 1801, 10.1158/1078-0432.CCR-06-1432 Gollob, 2007, Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer, J Clin Oncol, 25, 3288, 10.1200/JCO.2007.10.8613 Ryan, 2007, Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group, J Clin Oncol, 25, 3296, 10.1200/JCO.2007.11.1047 Bracarda, 2008, Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-a2a (IFN) in metastatic renal cell carcinoma (MRCC) (RAPSODY): GOIRC Study 0681 Jonasch, 2010, Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis, Cancer, 116, 57 Niwakawa, 2011, Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma, Invest New Drugs Rini, 2008, Is sorafenib plus interferon alpha 2b safe and effective in patients with renal cell carcinoma?, Nat Clin Pract Urol, 5, 132, 10.1038/ncpuro1036 Motzer, 2009, Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma, Clin Genitourin Cancer, 7, 28, 10.3816/CGC.2009.n.005 Tamaskar, 2008, A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab for patients (pts) with metastatic renal cell carcinoma (mRCC) Dandamudi, 2010, A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): a Cytokine Working Group study (CWGS), J Clin Oncol, 28 Procopio, 2011, Sorafenib with interleukin-2 vs. sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial, Br J Cancer, 104, 1256, 10.1038/bjc.2011.103 Larn, 2011, Phase I study of high-dose interleukin (HD-IL2) and sorafenib in patients with metastatic clear cell renal cell carcinoma (RCC) and melanoma Amato, 2006, Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma, Cancer, 106, 1498, 10.1002/cncr.21737 Amato, 2008, Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma, Am J Clin Oncol, 3, 237, 10.1097/COC.0b013e31815e4505 Merchan, 2009, Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients, J Clin Oncol, 27 Hainsworth, 2010, Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma, J Clin Oncol, 28, 2131, 10.1200/JCO.2009.26.3152 Escudier, 2010, Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial, J Clin Oncol, 28 Patel, 2009, Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma, Clin Genitourin Cancer, 7, 24, 10.3816/CGC.2009.n.004 Patnaik, 2007, A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies, J Clin Oncol, 25 Kroog, 2009, Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma, J Clin Oncol, 27 Harzstark, 2009, A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma, J Clin Oncol, 27 Cen, 2009, A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCC), J Clin Oncol, 27, Abs e16056, 10.1200/jco.2009.27.15_suppl.e16056 Molina, 2011, Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC) Kabbinavar, 2011, A phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC) Feldman, 2009, Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma, J Clin Oncol, 27, 1432, 10.1200/JCO.2008.19.0108 Sosman, 2008, Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC), J Clin Oncol, 26 Rini, 2009, A phase I study of sunitinib plus bevacizumab in advanced solid tumors, Clin Cancer Res, 15, 6277, 10.1158/1078-0432.CCR-09-0717 Azad, 2008, Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity, J Clin Oncol, 26, 3709, 10.1200/JCO.2007.10.8332 Shahbazian, 2006, The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity, EMBO J, 25, 2781, 10.1038/sj.emboj.7601166 Hainsworth, 2005, Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib, J Clin Oncol, 23, 7889, 10.1200/JCO.2005.01.8234 Bukowski, 2007, Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer, J Clin Oncol, 25, 4536, 10.1200/JCO.2007.11.5154 Hainsworth, 2007, Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial, Clin Genitourin Cancer, 5, 427, 10.3816/CGC.2007.n.030 Ryan, 2008, A dose-escalation phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC) Motzer, 2010, Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma, Am J Clin Oncol, 33, 614, 10.1097/COC.0b013e3181c4454d Porta, 2009, Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors, J Urol, 182, 2569, 10.1016/j.juro.2009.08.085 Schreeder, 2008, Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma, J Clin Oncol, 26 Allerton, 2008, Phase I report from a multicenter trial of perifosine (PERI)+sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC), J Clin Oncol, 26 Flaig, 2010, Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib, Br J Cancer, 103, 796, 10.1038/sj.bjc.6605868 Rini, 2011, Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma, Cancer, 117, 758, 10.1002/cncr.25639 Rini, 2011, AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC). A randomized, double-blind, placebo-controlled, phase II study Choi, 2005, Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model, Curr Oncol Rep, 7, 307, 10.1007/s11912-005-0055-4 Grothey, 2008, Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107, J Clin Oncol, 26, 183, 10.1200/JCO.2007.13.8099 Folkman, 2005, Antiangiogenesis agents, 2865 Dempke, 2009, Resistance to EGF-R (erbB-1) and VEGF-R modulating agents, Eur J Cancer, 45, 1117, 10.1016/j.ejca.2008.11.038 Rini, 2008, Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma, J Clin Oncol, 26, 3743, 10.1200/JCO.2007.15.5416 Shepard, 2008, A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab, J Clin Oncol, 26 Stadler, 2010, Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America, Cancer, 116, 1272, 10.1002/cncr.24864 Beck, 2011, Final results of the European advanced renal cell carcinoma sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings, Ann Oncol, 10.1093/annonc/mdq651 Di Lorenzo, 2009, Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer, J Clin Oncol, 27, 4469, 10.1200/JCO.2009.22.6480 Sepulveda, 2008, Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): analysis for safety and activity on sunitinib progressive pts, J Clin Oncol, 26 Mancuso, 2008, Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR TKI antiangiogenic treatment, J Clin Oncol, 26 Garcia, 2010, sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab, Cancer, 116, 5383, 10.1002/cncr.25327 Sablin, 2009, Sequential sorafenib and sunitinib for renal cell carcinoma, J Urol, 182, 29, 10.1016/j.juro.2009.02.119 Dudek, 2009, Sequential therapy with sorafenib and sunitinib in renal cell carcinoma, Cancer, 115, 61, 10.1002/cncr.24009 Eichelberg, 2008, Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis, Eur Urol, 54, 1373, 10.1016/j.eururo.2008.07.051 Tamaskar, 2008, Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy, J Urol, 179, 81, 10.1016/j.juro.2007.08.127 Richter, 2009, Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib Zimmermann, 2009, Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib, Oncology, 76, 350, 10.1159/000209961 Choueiri, 2010, Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review, BJU Int, 105, 1247, 10.1111/j.1464-410X.2009.08972.x Porta C, Procopio G, Cartenì G, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicentre retrospective analysis of 189 patient cases. BJU Int; in press. Kontovinis, 2011, Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study, Med Oncol Buchler, 2011, Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry, Ann Oncol Paez-Ribas, 2009, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis, Cancer Cell, 15, 167 Porta, 2011, Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review, Eur J Med Clin Oncol, 2, 67 Rini, 2011, Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial, J Clin Oncol, 29 Rini, 2009, Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma, J Clin Oncol, 27, 4462, 10.1200/JCO.2008.21.7034 Tannir, 2009, Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: efficacy and safety results, J Clin Oncol, 27 Motzer, 2010, Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors, Cancer, 116, 4256, 10.1002/cncr.25219 Grunwald, 2011, Everolimus in patients with metastatic renal cell carcinoma (mRCC) who are intolerant or have progressed after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: an international expanded access program (EAP) Wood, 2008, Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy, J Clin Oncol, 26 Gerullis, 2010, Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma, Med Oncol, 27, 373, 10.1007/s12032-009-9220-1 Mackenzie, 2011, Temsirolimus in VEGF-refractory metastatic renal cell carcinoma, Ann Oncol, 22, 145, 10.1093/annonc/mdq320 Zama, 2010, Sunitinib rechallenge in metastatic renal cell carcinoma patients, Cancer, 116, 5400, 10.1002/cncr.25583 Di Lorenzo, 2010, Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma, Eur Urol, 10.1016/j.eururo.2010.09.008 Blesius, 2010, Are TKIs still active in patients treated with TKI and everolimus? Experience from 36 patients treated in France in the RECORD-1 trial, Ann Oncol, 21 Gruenwald, 2010, Antitumor activity of tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC) Porta, 2010, Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma, Oncol Rev, 4, 1, 10.1007/s12156-010-0039-y Vickers, 2010, Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy, Urology, 76, 430, 10.1016/j.urology.2009.12.031 Heng, 2011, Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy Motzer, 2009, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, J Clin Oncol, 27, 3584, 10.1200/JCO.2008.20.1293 Escudier, 2009, Sequential therapy in renal cell carcinoma, Cancer, 115, 2321, 10.1002/cncr.24241